Scarica l'app Stockscreener
101.55
0.54%
0.55
Pre-mercato:
101.98
0.43
+0.42%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MIRM Giù?
Forum
Previsione
Mirum Pharmaceuticals Inc Borsa (MIRM) Ultime notizie
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised) - TradingView
MIRM Maintained by Citizens -- Price Target Raised to $146 - GuruFocus
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review - TradingView
H.C. Wainwright reiterates Mirum Pharmaceuticals stock rating at buy By Investing.com - Investing.com Canada
Citizens raises Mirum Pharmaceuticals stock price target on drug deal - Investing.com
Citizens raises Mirum Pharmaceuticals stock price target on drug deal By Investing.com - Investing.com Canada
Mirum and Incyte's zilurgisertib shows positive phase 2 data in FOP - MSN
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva - lincolnjournal.com
Here's what key metrics tell us about Mirum Pharmaceuticals (MIRM) Q1 earnings - MSN
MIRM Maintains Overweight Rating -- Price Target Raised to $150 - GuruFocus
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Mirum Pharmaceuticals (NASDAQ:MIRM) Given New $150.00 Price Target at Morgan Stanley - MarketBeat
Why is Mirum Pharmaceuticals (MIRM) down 10.1% since last earnings report? - MSN
Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) CFO Sells 5,000 Shares of Stock - MarketBeat
Mirum Pharmaceuticals CFO Eric Bjerkholt sells $469k in shares - Investing.com UK
Mirum Pharmaceuticals CFO Eric Bjerkholt sells $469k in shares By Investing.com - Investing.com India
Mirum Pharmaceuticals (MIRM) CFO sells 5,000 shares after option exercise - Stock Titan
CenterBook Partners LP Purchases 37,010 Shares of Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum Pharmaceuticals, Inc. $MIRM Shares Sold by Clearbridge Investments LLC - MarketBeat
Mirum (MIRM) President and COO exercises options, boosts direct share holdings - Stock Titan
5,000-share resale notice for MIRM (NASDAQ: MIRM) affiliate; prior sale noted - Stock Titan
Mirum Pharmaceuticals Q1 2026 Earnings: EPS Misses Estimates Significantly, Shares Edge HigherEarnings Quality Analysis - newsline.com
Mirum Pharmaceuticals (MIRM) Edges Higher as Bulls Test Resistance Near $98BPI Bear Confirmed - newsline.com
Mirum Pharmaceuticals, Inc. Balance Sheet – XETR:08D - TradingView
EBITDA of Mirum Pharmaceuticals, Inc. – XETR:08D - TradingView
Discipline and Rules-Based Execution in MIRM Response - Stock Traders Daily
Why Is Mirum Pharmaceuticals (MIRM) Down 10.1% Since Last Earnings Report? - Yahoo Finance
Earnings call transcript: Mirum Pharmaceuticals Q1 2026 results reveal strong revenue growth - Investing.com
Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026 - BioSpace
Mirum and Incyte to present FOP drug trial results at ENDO 2026 - Investing.com Canada
Mirum and Incyte to present zilurgisertib study results at ENDO 2026 - StreetInsider
Mirum Pharmaceuticals (MIRM) Reports Positive Phase 2b Data for Volixibat in PSC at EASL Congress - Insider Monkey
Mirum Pharmaceuticals Insider Sold Shares Worth $2,875,103, According to a Recent SEC Filing - Moomoo
HC Wainwright & Co. Maintains Mirum Pharmaceuticals (MIRM) Buy Recommendation - MSN
Mirum director Saira Ramasastry sells $397,700 of company stock By Investing.com - Investing.com South Africa
Insider Sell: Saira Ramasastry Sells 3,977 Shares of Mirum Pharm - GuruFocus
Mirum CEO Peetz sells $2.88m in stock after exercising options - Investing.com Nigeria
Mirum director Saira Ramasastry sells $397,700 of company stock - Investing.com
Mirum CEO Peetz sells $2.88m in stock after exercising options By Investing.com - Investing.com India
Mirum (MIRM) director converts 3,977 restricted stock units into common shares - Stock Titan
Mirum Pharmaceuticals (MIRM) CEO logs option exercise and 30K-share sale - Stock Titan
Mirum Pharmaceuticals (MIRM) director converts 3,977 RSUs into 9,680-share holding - Stock Titan
Mirum Pharmaceuticals (MIRM) director sells 3,977 shares under 10b5-1 plan - Stock Titan
MIRM Initiated Coverage by Citigroup -- Rating Set to Buy - GuruFocus
Insider sale and option exercise — MIRM: 40,985 shares sold, 30,000 planned - Stock Titan
3,977-share planned restricted-stock sale by MIRM (NASDAQ: MIRM) - Stock Titan
Citizens reiterates Mirum Pharmaceuticals stock rating on pipeline - Investing.com
Citizens reiterates Mirum Pharmaceuticals stock rating on pipeline By Investing.com - Investing.com Canada
Mirum Pharmaceuticals (MIRM) Pushes Higher, Approaches Key ResistanceBullish Percent Index - newsline.com
Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026 - Weekly Voice
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):